natgillin/translations-raw huggingface dataset:
A synergistic herbicidal mixture as claimed in claims 1 to 2 in which the sulfonamide is selected from the group consisting of florasulam, flumetsulam, metosulam, penoxulam, cloransulam-methyl, and diclosulam, including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
imazamoks kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom; i metazaklor i kvinmerak uključujući njihove odgovarajuće izomere, kao i njihove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom.
The present invention provides |a compound of formula (I): wherein: 
HR P20140884 T1 PATENTNI ZAHTJEVI Spoj čija je formula (I): gdje je:
The power tool of claim 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18 or 19 wherein the switch requires one hand of an operator on it while another hand of the operator pulls a trigger. 
Električni alat u skladu s patentnim zahtjevom 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 ili 19, naznačen time što operator mora jednu ruku držati na prekidaču, a drugom rukom mora stisnuti taster.
subjecting the beverage to an external isostatic pressure exceeding the equilibrium pressure of the beverage by at least 1.0 bar, preferably 1.2-60 bar, more preferably 1.5-10 bar, most preferably about 2 bar. 
HR P20171971 T1 2 bara, navedeni ultra fini mjehurići koji imaju glavnu dimenziju manju od 100nm, kao što je _20-60nm, poželjno oko 40nm, i, podvrgavaju navedeni napitak vanjskom izostatičkom pritisku koji prelazi navedeni ravnotežni pritisak navedenog napitka za najmanje 1.0 bar, poželjno 1.2 -60 bara, poželjnije 1.5-10 bara, najpoželjnije 2 bara.
The roulette wheel apparatus according to claim 1, wherein the ball launcher comprises a rotatable element and a fixed element defining a gap between them and arranged to accelerate a roulette ball passing through the gap. 
Uređaj s kolom za rulet u skladu s patentnim zahtjevom 1, naznačen time što lanser kuglice sadrži zakretljivi element i fiksni element koji omeđuju procjep između sebe i služe za ubrzavanje kuglice za rulet koja prolazi kroz procjep.
Biotin for use according to any one of claims 1 to 9, characterized in that it is in the form of a slow release composition. 
Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je u obliku pripravka s usporenim oslobađanjem.
The veterinary or agricultural composition according to claim 24, wherein the antitrematodal agent is selected from the group consisting of miracil D, mirasan, praziquantel, clonazepam, meclonazepam, oltipraz, lucanthone, hycanthone, oxamniquine, amoscanate, niridazole, nitroxybil, hexachlorophene, bithionol, bithionol sulfoxide, menichlopholan, tribromsalan, oxyclonazide, clioxanide, rafoxanide, brotianide, bromoxanide, closantel, triclabendazole, diamfenetide, chlorsulon, hetolin and emetine. 
Veterinarski ili agrikulturni sastav prema zahtjevu 24, naznačen time, da je antitrematodno sredstvo odabrano iz skupine koja se sastoji od sljedećih: miracil D, mirasan, prazikvantel, klonazepam, meklonazepam, oltipraz, lukanton, hikanton, oksamnikin, amoskanat, niridazol, nitroksibil, heksaklorofen, bitionol, bitionol-sulfoksid, meniklofolan, = tribromsalan, = oksiklonazid, klioksanid, rafoksanid, = brotianid, -bromoksanid, = klozantel, triklabendazol, diamfenetid, klorsulon, hetolin i emetin.
Thus when the packaging is moved out of a specific area e.g. out between two signal detecting means, it is possible to activate an alarm. 
U tom slučaju, kada se pakiranje makne iz specifičnog područja, na primjer, van iz područja koje se nalazi između dva sredstva za detektiranje signala, moguće je aktivirati signal.
and a T cell receptor comprising: 
(I) T staničnog receptora koji sadrži:
The fusion protein according to claim 3 or 4, having the amino acid sequence set forth in SEQ ID NO: 104. 
Pripravak prema zahtjevu 1, naznačen time da navedeni polipeptid sadrži sekvencu amino kiseline iz SEQ ID NO: 147, SEQ ID NO:148 ili SEQ ID NO:299.
After stirring at 60 °C for 1 hour, the reaction mixture is allowed to cool to room temperature and then diluted with ethyl acetate/ether (200 ml of a 1:1 mixture) and water (150 ml). 
Nakon miješanja 1 sat pri 60C, reakcijsku smjesu se pusti ohladiti na sobnu temperaturu i zatim se razrijedi s etil acetat/eterom (200 ml 1:1 mješavine) i vodom (150 ml).
In a second embodiment of the first aspect the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein B is selected from 
NOS OD, do 3. = Spoj iz patentnog zahtjeva 1, ili farmaceutski prihvatljiva so log spoja, pri čemu B je odabrano od
gastroresistant microgranules containing a hydrate or solvate form of rifaximin B alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in an amount comprised between 100 and 800 mg, ii) pharmaceutically acceptable extragranular excipients, and optionally iii) a film-forming coating 
želučanootporne mikrogranule, koje sadrže hidratni ili solvatni oblik rifaksimina B, sam ili u smjesi s drugim kristalni, hidratnim, solvatnim ili amorfnim oblicima rifaksimina, u količini koja se kreće između 100 i 800 mg, ii) farmaceutski prihvatljive ekstragranularne pomoćne tvari i, izborno, iii) oblogu koja tvori film, gdje ukupna količina ekstragranularnih pomoćnih tvari koje sadrži tableta ne prelazi 30% težine tablete.
The compound or composition for use according to claim 1, wherein the disease or disorder is fallopian tube cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika.
A nucleic acid construct or vector comprising the nucleic acid sequence according to claim 4. 
Konstrukt nukleinske kiseline ili vektor naznačen time što sadrži sekvencu nukleinske kiseline prema patentnom zahtjevu 3.
FIG. 3 provides various dimensions, in millimeters, of a preferred embodiment. 
Slika 3 prikazuje razne dimenzije, u milimetrima, preferirane izvedbe.
The salt of Claim 8 further characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 159.0, 150.9, and 40.7 ppm. 
Sol iz Zahtjeva 8, nadalje, naznačena time, da spektar nuklearne rezonance krutog ugljika-13 CPMAS pokazuje signale na 159.0, 150.9, i 40.7 ppm.
Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethylformamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran. 
Primjeri pogodnih otapala uključuju: ugljikovodike, koji mogu biti aromatski, alifatski ili cikloalifatski ugljikovodici, poput heksana, cikloheksana, benzena, toluena i ksilena; amide, poput dimetilformamida; alkohole, poput etanola i metanola, te etere, poput dietil-etera 1 tetrahidrofuran.
in formula If-1 when: is H, and Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1-haloalkyl, and 
u formuli If-1 kada: je H, i Ar1 je 6-člani aril izborno supstituiran s jednom ili više skupina odabranih od halo, cijano, C1-C3 alkil, C1-haloalkil, i
Universal and rapid covering system according to claim 1, wherein said cover (1) comprises of a reinforcing fabric (6) along one or more ridge lines that can terminate on both ends with a hook (9). 
Univerzalan 1 brz sustav prekrivanja prema zahtjevu 1, pri čemu navedeni prekrivač (1) sadrži tkaninu za ojačanje (6) duž jedne ili više preklopnih linija, a koje na oba kraja mogu imati kuku (9).
Exemplary Fc modifications that enhance Fc binding to the FcyRIIb are S267E/L328F and E233D/G237D/H268D/P271G/A330R (residue numbering according to the EU Index). Another embodiment of the invention is an isolated antibody that binds human CD134, comprising a light chain variable region (VL) of SEQ ID NO: 98 and a heavy chain variable region (VH) comprising heavy chain complementarity determining regions (HCDR)s HCDR1, HCDR2 and HCDR3, optionally having 1, 2 or 3 amino acid substitutions in the VL of SEQ ID NO: 98. 
Izolirano protutijelo koje veže humani CD 134, koje sadrži varijabilnu regiju lakog lanca (VL) od SEK ID BR: 98, ili koje ima 1, 2 ili 3 supstituciju aminokiselina u VL-u od SEK ID BR: 98 i varijabilnu regiju teškog lanca (VH), naznačeno time, da VH sadrži sekvence aminokiselina od SEK ID BR: 134, ili ima 1, 2 ili 3 supstituciju aminokiselina u VH od SEK ID BR: 134 ili VH sadrži sekvence aminokiselina od SEK ID BR: 97, ili ima 1, 21li 3 supstituciju aminokiselina u VH od SEK ID BR: 97, naznačeno time, što a.
reacting a compound represented by the formula (I-3): wherein R3, X and m are as defined above, and na is an integer of from 1 to 2, with a nucleophilic reagent; 
»Bm NN We Na (t-3) pri čemu su R*, X i m kao što je definirano gore, a na je cijeli broj od 1-2, s nukleofilnim reagensom;
G is any of the following Ga to Ge: 
G je bilo koji od sljedećih G* do G*:
Very few of these drugs have proven effective. 
Malobrojni među tim lijekovima su pokazali učinkovitost.
the Fc domain comprises a hinge domain, a CH2 domain and a CH3 domain; and/or a leader sequence, such as the human VK3LP peptide, is coupled to the N-terminus of the RNase or the N-terminus of the DNase. 
(c) Fc domena sadrži zglobnu domenu, CH2 domenu i CH3 domenu; i/ili (d) vodeća sekvenca, kao što je ljudski VK3LP peptid, spojena je na N-terminalni kraj RNaze ili N-terminalni kraj DNaze.
1999) and the results show that most of the Ig-like domains display less than 10% sequence identity and that in the Ig-like domains most of the residues constituting the common core are hydrophobic. 
1999) te su rezultati pokazali da većina Ig-sličnih domena na razini sekvencije ima sličnost manju od 10% i da su u većini tih domena aminokislinski ostaci u zajedničkoj jezgri hidrofobni.
The mouse of (1), wherein the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region. 
(a) mišu nedostaje lokus varijabilne regije lakog lanca endogenog mišjeg imunoglobulina koji preuređenjem može tvoriti gen koji kodira varijabilnu regiju x miša;
A compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein: 
HR P20181041 T1 HR P20181041 T1 PATENTNI ZAHTJEVI 1. - Spoj predstavljen slijedećom strukturnom formulom:
the first sachet comprises: 
A) prva vrećica sadrži:
mixing the binder of step b) with the aqueous mineral pigment material suspension of step a) and adjusting the solids content of the obtained suspension so that it is ≥ 45 to 95 wt.-%, preferably from 45 to 80 wt.-%, based on the total weight of the suspension; grinding the aqueous mineral material suspension of step c). 
C) miješanje veziva iz koraka b) s vodenom suspenzijom mineralnog pigmentnog materijala iz koraka a) te podešavanje sadržaja krutina dobivene suspenzije tako da bude > 45 do 95% tež., poželjno od 45 do 80% tež., u odnosu na ukupnu težinu suspenzije; d) usitnjavanje vodene suspenzije mineralnog materijala 12 koraka c), gdje se u koraku c) vezivo dodaje vodenoj suspenziji mineralnog pigmenta u količini od 0.1 do 10.0% tež., u odnosu na ukupnu težinu suspenzije.
The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. 
Pripravci mogu biti u oblicima poput suspenzija, otopina ili emulzija u uljnim ili vodeni vehikulumima, te mogu sadržavati formulacijska sredstva, poput sredstava za suspendiranje, stabiliziranje i(li) dispergiranje.
The therapeutic hosiery item according to the invention can be used, therefore, without problems like an elegant hosiery item. 
Zbog toga se terapeutska čarapa prema izumu može bez problema upotrijebiti kao elegantna čarapa.
The use or the compound or a pharmaceutically acceptable salt thereof, for use in a method of treatment of claim 14, wherein said disorder is a cell proliferative disorder associated with aberrant Wnt signaling activity selected from the group colorectal cancer, colorectal carcinoma, breast cancer, head and neck squamous cell carcinoma, esophageal cancer, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilm's tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer. 
Uporaba ili spoj ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku liječenja prema zahtjevu 14, naznačen(a) time, da spomenuti poremećaj je stanični proliferativni poremećaj povezan sa zastranjivanjem signalnog djelovanja WNT, koji je odabran iz skupine koju čine kolorektalni rak, kolorektalni karcinom, rak dojke, karcinom rožnatih stanica glave 1 vrata, ezofagealni rak, ezofagealni karcinom rožnatih stanica, rak ne-malih stanica pluća, rak želudca, rak gušterače, leukemija, limfom, neuroblastom, retinoblastom, sarkom, osteosarkom, hondosarkom, Ewingov sarkom, rabdomiosarkom, tumor mozga, Wilmov tumor, karcinom bazalnih stanica, melanom, rak glave i vrata, cervikalni rak i rak prostate,
An apparatus (1) for upgrading a stream of biogas (2), comprising at least methane and CO2, to biomethane, comprising: 
Uređaj (1) za preradu struje bioplina (2) proizvedena bakterijskom digestijom organskih ostataka u anaerobnim uvjetima, koja u najmanju ruku sadrži metan i CO;, u biometan, naznačen time što sadrži:
The compounds are also useful in combination with androgens, estrogens, progesterones, and antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids, and in contraception, as well as in combination with an angiotensin-converting enzyme inhibitor, an angiotensin II-receptor antagonist, or a renin inhibitor for the treatment of uterine fibroids. 
Spojevi su također korisni u kombinaciji s androgenima, estrogenima, progesteronima, te antiestrogenima i antiprogestogenima za liječenje endometrioze, fibroida, te kod kontracepcije, kao i u kombinaciji s inhibitorom angiotenzin-konvertirajućeg enzima, antagonistom receptora angiotenzina II, ili reninskim inhibitorom kod liječenja fibroida maternice.
R3a represents a hydrogen atom or a fluorine atom; and substituent group a has the same meaning as described in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof in which "prodrug" means a compound wherein one or more carboxy groups of a compound represented by the above general formula (Ia) is substituted by a group forming a prodrug, in which the group forming a prodrug is selected from the group consisting of C1-6 alkyl, C1-6 alkyl-COO-C1-6 alkylene, C1-6 alkyl-OCOO-C1-6 alkylene, C3-8 cycloalkyl-OCOO-C1-6 alkylene, mono(di)hydroxy C1-6 alkyl, mono(di)hydroxy C1-6 alkyl-OCOO-C1-6 alkylene, C1-6 alkoxy C1-6 alkoxy C1-6 alkyl, mono(di)C1-6 alkylamino C1-6 alkyl, 3 to 8-membered heterocycloalkyl C1-6 alkyl, and C1-6 alkyl-OCO-amino C1-6 alkylene. 
R** predstavlja atom vodika ili atom fluora; i grupa supstituenata o, ima isto značenje kako je opisano u zahtjevu 1, ili njihov prolijek, ili njihovu farmaceutski prihvatljivu sol, pri čemu "prolijek" označava spoj u kojem je jedna ili više karboksi skupina spoja predstavljenog gore općom formulom (Ia) supstituirana skupinom koja daje prolijek, gdje se skupina koja daje prolijek izabire iz grupe koja obuhvaća Ci.4 alkil, C,.4 alkil-COO-C;.s4 alkilen, Ci.4 alkil- OCOO-C,.4 alkilen, C3.8 cikloalkil-OCOO-C;.4 alkilen, mono(di)hidroksi C,.4 alkil, mono(di)hidroksi C,.4 alkil- OCOO-Ci,.s alkilen, C,4 alkoksi Cis alkoksi C;sg alkil, mono(di)C;s4 alkilamino Cig alkil, 3 do 8-eročlani heterocikloalkil C1.g alkil, i Cig alkil-OCO-amino C;.g alkilen.
Conveyor according to claim 1, wherein the plunger drive is adapted to place the plunger in a third position in which it by its form and positioning substantially covers the input opening, and whereby a returnable item which has been received in the input area is blocked from falling through the input opening by remaining the returnable item on the plunger when the plunger is placed in the third position. 
Prema gore orijentirano skladište prema patentnom zahtjevu 19, naznačeno time, što je pogon klipa prilagođen da postavi klip u treći položaj u kojem on svojim oblikom i pozicioniranjem značajno pokriva ulazni otvor, i pri čemu je povratni artikal koji je primljen u ulaznom području blokiran od pada kroz ulazni otvor tako što ostaje na klipu kada se klip stavi u treći položaj.
A process for obtaining compounds of the formula VIII as claimed in claims 6 or 7, which comprises reacting a compound of the formula VI with the compound of formula VII W-CH2-A2-R15 (VII) wherein W is a halogen or a sulfonyl ester, and A2 and R15 are as defined in claims 6 or 7 to give a compound of formula VIII. 
Postupak dobivanja spojevi formule VIII u skladu s patentnim zahtjevima 6 ili 7, naznačen time što se sastoji u reakciji spoja formule VI s spojem formule VII
The combined CH2Cl2 layers dried (Na2SO4/actvated charcoal), filtered and concentrated to give brown solid which triturated with ether and filtered to afford intermediate 9 as a light brown powder (11.81 g, 38%). 
Kombinirani CH,C1, slojevi su sušeni (Na,SOy/aktivni ugljen), filtrirani i koncentrirani da bi se dobila smeđe čvrsta supstanca koja je triturirana sa eterom i filtrirana da bi se dobio Intermedijer 9 kao svijetlo smedi prašak (11.81 g, 38%).
is hydrogen; is hydrogen; (C1-C4)alkyl; cyclopropylmethyl; benzyl; or heterocyclylmethyl wherein the heterocyclyl group is selected from furanyl, tetrahydrofuranyl, and pyridinyl optionally substituted with a methoxy group; 
R' je vodik; R' je vodik; (Ci-Cq)alkil; ciklopropilmetil; benzil; ili heterociklilmetil, gdje se heterociklilnu skupinu bira između furanila, tetrahidrofuranila i piridinila izborno supstituiranog s metoksi skupinom;
The sifted materials were blended together. 
Prosijani materijali su pomiješani zajedno.
A package according to claim 16, which further comprises an active compound (c), as defined in claim 8 or 9. 
Paket sukladno patentnom zahtjevu 16, naznačen time, da dodatno sadrži djelatni spoj (c) kako je definiran u patentnom zahtjevu 8 ili 9.
While the aforementioned embodiment teaches that the number of orifices may be increased according to a geometric sequence from the lowest plate to the uppermost plate, other sequences may be used so long as the number of orifices increases from the lowest plate to the uppermost plate. 
Sustav prema zahtjevu 3, naznačen time da mjerna prigušnica sadrži prvu ploču i drugu ploču, te je prva ploča postavljena bliže sustavu za kontrolu protoka krutih tvari od druge ploče.
At least one Nitric Oxyde radical inhibitory drug; as a combination product for simultaneous, separate or spread over time administration for use in preventing and/or treating the remyelination blockage in a disease associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype, wherein: 
barem jedan inhibitorni lijek radikala dušikovog oksida; kao kombinacijski proizvod za istodobnu, odvojenu ili primjenu raširenu tijekom vremena za uporabu u sprječavanju 1/ili liječenju remijelinizacijske blokade u bolesti koja je povezana s ekspresijom HER V-W proteina ovojnice (ENV), posebice njegovog MSRV podtipa, naznačen time što:
The pharmaceutical composition of claim 1 or claim 11, wherein the compound of Formula I is any one of the compounds of the table below, Cmpd # 
Farmaceutski sastav prema zahtjevu 1 ili zahtjevu 10, gdje je spoj formule I bilo koji spoj iz donje tablice, ili njegova farmaceutski prihvatljiva sol.
This means that the MMVF substrates of the present invention have particular utility in areas where it is important to have a low lambda value in environments where the temperature is above 300° C., such as for use as (a) technical insulation or (b) fire protection in an industrial or marine environment. 
Uporaba MMVF supstrata sukladno bilo kojem od zahtjeva 16 do 19, ili MMVF supstrat oblikovan od MMVE dobivenog postupkom sukladno bilo kojem od zahtjeva 1 do 9, kao (a) tehnička izolacija ili (b) za zaštitu od požara u industrijskom ili morskom okolišu.
The compounds of claim 1 wherein R4 is phenyl substituted at the 4-position with hydroxy, C1-3alkylaminocarbonyl, or aminocarbonyl, and substituted at the 2- and 6-positions with methyl substituents. 
Spoj prema zahtjevu 1 maznačen time da R' je fenil supstituiran na 4-poziciji sa hidroksi, C,salkilaminokarbonilom ili aminokarbonilom i supstituiran na 2- poziciji i 6-poziciji sa metil supstituentima.
An antibody or antigen-binding fragment thereof for use as claimed in any preceding claim, wherein the antibody is produced by cells having ATCC Access. No. 
Rekombinantna stanica koja eksprimira protutijelo koje se specifično veže na endosijalin, naznačena time što navedeno protutijelo proizvode stanice s ATCC pristupnim br.
step 1: formation of a diastereoisomeric tartrate salt of the triazine derivative with a single enantiomer of tartaric acid by reaction of a salt of the compound of formula (I) with a single enantiomer of tartaric acid, 
- korak 1: tvorbu diastereoizomerne tartratne soli derivata triazina reakcijom soli derivata triazina sa jednim enantiomerom vinske kiseline,
In such an embodiment, both the feed surface and the polymerizable liquid can be in fluid contact with the same compressed gas (e.g., one comprising from 20 to 95 percent by volume of oxygen, the oxygen serving as the polymerization inhibitor. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 11 do 15, naznačen time da polupropusni element nadalje sadrži dovodnu površinu odvojenu od navedene površine za oblikovanje; gdje je opcionalno dovodna površina je u fluidnom kontaktu s inhibitorom polimerizacije, tako da se osigura spomenuti izvor inhibitora polimerizacije.
evaporating the resulting solution to dryness; 
(iva) isparavanja rezultirajuće otopine do isušenja;
W is selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl and alkoxy of from 1 to 3 carbon atoms. 
W se bira iz skupine koja sadrži vodik, fluoro, kloro, bromo, trifluorometil i alkoksi sa 1 do 3 ugljikova atoma.
Transdermal therapeutic system according to claim 15 wherein the dosage unit has 0.525-2.1 mg Gestodene per dosage unit together with 0.55 mg Ethinylestradiol in a polyisobutylene-containing matrix with a size of 11 cm2. 
Transdermalni terapijski sustav prema zahtjevu 8 naznačen time da jedinica doziranja ima 0.525 ili 1.05 mg Crestodena po jedinici doziranja zajedno s 0.55 mg Etinilestradiola u matrici koja sadrži poliizobutilen s veličinom od 11 cm".
Loading and elution conditions were similar as for r-hIL-18BP capture process (see below). 
Uvjeti nanošenja i eluacije bilo su slični kao i u postupko hvatanja r-hIL-18BP (vidi dolje).
is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, and 
(7) supstituirani i nesupstituirani alkil, (8) -COR2, i
Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. 
Primjeri takvih anorganskih soli su one sa klorovodičnom, bromovodičnom, sumpornom, sulfamatnom, fosfornom i nitratnom kiselinom.
The compound for use of claim 1, wherein R1, R2 and R3 are hydrogen; 
Spoj u skladu s patentnim zahtjevom 3, naznačen time, da su R1, R2, R3 vodik;
represents a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl carbonyl group, a benzoyl group or a C1-3 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom or a hydroxyl group; and/or 
R4 predstavlja C,2 alkoksikarbonilnu skupinu, C34 cikloalkilkarbonilnu skupinu, benzoilnu skupinu ili C,.g alkilnu skupinu, izborno supstituiranu s 1 do 4 supstitucnta, koje sc bira između atoma halogena ili hidroksilne skupinc; i/ili
NMR=nuclear magnetic resonance spectrometry 
NMR = spektrometrija nuklearne magnetske rezonance PG